New advances in engineering and biomedical technology have enabled recent efforts to capture essential aspects of human physiology in microscale, in-vitro systems. The application of these advances to experimentally model complex processes in an integrated platform -commonly called a 'human-on-a-chip (HOC)' -requires that relevant compartments and parameters be sized correctly relative to each other and to the system as a whole. Empirical observation, theoretical treatments of resource distribution systems and natural experiments can all be used to inform rational design of such a system, but technical and fundamental challenges (e.g. small system blood volumes and context-dependent cell metabolism, respectively) pose substantial, unaddressed obstacles. Here, we put forth two fundamental principles for HOC design: inducing in-vivo-like cellular metabolic rates is necessary and may be accomplished in vitro by limiting O 2 availability and that the effects of increased blood volumes on drug concentration can be mitigated through pharmacokinetics-based treatments of solute distribution. Combining these principles with natural observation and engineering workarounds, we derive a complete set of design criteria for a practically realizable, physiologically faithful, fi ve-organ millionth-scale (× 10 −6 ) microfl uidic model of the human body.
INTRODUCTION
Advances in micro-scale engineering, cell sourcing and culture techniques are presenting new opportunities to recapitulate key structural and functional characteristics of the human body in controlled, in-vitro, experimental systems. Already, organ-level devices (commonly called 'organs-on-a-chip') are quite prolifi c 1−3 . Eff orts at devising systems-level platforms (i.e. HOCs) hold even greater promise 4−7 . Ideally, these small HOCs would predict the eff ects of potential drugs or toxins on the human body 8−10 , signifi cantly reducing costs associated with animal and human clinical trials in the drug discovery pipeline, clarifying mechanisms of human health and disease and introducing new opportunities in personalized medicine. However, unresolved issues in both the design and fabrication of such systems present scientists and engineers with a complex, interdependent set of problems.
Animal basal metabolic rate (BMR) has been shown to scale with animal mass raised to some power 11 . Although there remains some debate as to the exact value of the exponent 12 , recent research has focused on how nutrient distribution networks generally control the relationship between organism size and metabolism 13, 14 . Thus, many important physical parameters scale with organism mass (M) raised to the power of a multiple of ¼ (e.g. metabolic rate, M ¾ ; heart rate, M −¼ ; and blood volume, M 1 ), called quarter-power scaling relationships (QPSRs). Th ese QPSRs 6, 15, 16 , along with order of magnitude estimates 17, 18 , residence time and physiologically based pharmacokinetic/pharmacodynamic (PB-PKPD) models 4,5,8,19−21 , empirical allometry 22, 23 and functional approaches 22−24 have all been used in the design of HOCs. Although these approaches do inform values for organ compartment size and other physiological parameters, they also present two classes of intractable problems in the design and construction of such systems. Th e fi rst type of problem is purely technical in nature (e.g. the need for microfl uidic systems of low circulating fl uid volume, but suffi cient tissue volume) and may eventually be solved by steady improvement in techniques and capabilities . We propose that these challenges themselves only merit concern so far as they aff ect the end output of the HOC. Th at is, the structure of a ×10 −6 HOC may assume strange and unexpected forms so long as the function -the cellular-and system-level behavior of the HOC -is accurate and relatable to human physiology. Th erefore, discrete parts of an HOC need not necessarily be confi ned by conventional notions of what constitutes "normal" or "physiologic". To that end, we focus on designing a ×10 −6 HOC capable of mimicking key functions of a macro human, specifi cally (1) cellular-and macro-scale BMRs and (2) basic pharmacokinetics. We further demonstrate how naturally-occurring biological systems may stray from structures of typical physiology (e.g. a hemoglobin-free vertebrate), yet produce species capable of adapting and surviving nonetheless. As modifi cation of any particular system parameter necessarily aff ects all others, both natural and artifi cial design alterations demand a holistic approach. Applying these general principles, we propose specifi c design parameters for an HOC that is practical in terms of fl uid-to-cell ratios and is a ×10 −6 miniaturization of the human body with regard to total cell mass, yet remains a faithful model of macroscopic human physiology with regards to cellular BMR, basic pharmacokinetics and inter-organ scaling.
CONTROL OF CELLULAR BMR
As predicted by QPSRs, cellular metabolic rate scales with animal mass 25, 26, 28 . However, cells cultured in vitro tend to operate at an elevated metabolic rate regardless of their organism of origin (Fig. 1a ) 25, 27 . Without accounting for this phenomenon, cells in an in-vitro HOC would have a high cellular BMR, more akin to cells in a mouse than in a human. Th us, the system BMR of the animal-on-a-chip diverges from that of the corresponding real animal; the magnitude of the error increases with animal size as μM ¼ (Fig. 1b) . For example, failure to consider the context-dependent behavior of cells in attempting to design a ×10 -6 model of a human would result in an HOC wherein the cellular BMR is high and thus approximates that of a mouse and the system BMR is also high and approximates that of a ×10 -6 elephant! Because of this non-linearity in scaling (i.e. M raised to a power ≠1), rational design -and control -of the metabolic infrastructure of an HOC is crucial. We have previously proposed that designers must force cells in an HOC to function as they would in the macroscopic human body -that is, designers must suppress cellular BMR to match in-vivo levels outlined in Fig. 1a , in a strategy termed metabolically supported scaling 24 .
Although others have demonstrated metabolic control by regulating glucose 29 , ions 30 , extracellular matrix (ECM) cues 31 and oxygen 24 , we propose to limit O 2 availability for the expressed purpose of suppressing cellular BMR and inducing a more in-vivo like response from an HOC. Not only does this approach more closely approximate conditions in the body than the hyperoxic conditions of incubator cell culture, but in-situ microfl uidic O 2 sensing and control is an established and active area of research 32−34 . To demonstrate that O 2 deprivation is a viable method for controlling cellular metabolic rate, we examine the behavior of human cell lines in atmospheric (20%) and physiotypic (7% and 2%) oxygen environments. Using AlamarBlue as an indicator of cellular respiration, we show that HepG2-C3A, HS-5, IMR-90 and HEK-293 cells all demonstrate signifi cant (p < 0.001) oxygen conformance. A similar eff ect has been noted by measuring oxygen consumption rather than AlamarBlue reduction as well as predicted numerically 35, 36 . As oxygen decreases, cellular metabolism follows -at physiotypic oxygen tension, cellular respiration is reduced by nearly fi vefold (Fig. 2) . Importantly, in no cases did AlamarBlue metabolism drop to zero indicating that, even aft er four hours culture in each O 2 atmosphere, the cells remained viable. Total cellular BMR is likely to be slightly higher than these measured values since our AlamarBlue indicator fails to respond to the anaerobic ATP production which yields ∼10× less energy than aerobic processes.
Although cellular BMR saw at most a fi vefold reduction, compared to the 10× theoretical diff erence between cells in vivo and in vitro (Fig. 1a) , these results demonstrate that oxygen deprivation is a viable strategy for reducing cellular BMR to be more in line with "natural" levels. Moreover, the results demonstrate that cells remained viable in pO 2 up to 10× lower than a conventional cell culture incubator (perhaps unsurprising given that such low O 2 levels are part of the in-vivo environment for most cells). While we do not claim that data implies a specifi c O 2 range for "optimal" cell function, it does, combined with existing theory, suggest a more "in-vivo-like" set of parameters than those used in conventional cell culture. While it is likely that other processes may be aff ected by this change in cell BMR (e.g. drug metabolism) that is precisely the point, as these changes are likely to more accurately refl ect cell behavior in the body. Th erefore, in contrast with suggested strategies to create a suitable oxygen-rich . (a-i) In-vitro cell culture of human cells leads to a cellular BMR ∼one order of magnitude larger than that of a normal human 25, 27 . (a-ii) A high-fidelity, physiologically relevant human-on-a-chip (HOC) should be designed with mechanisms to ensure cellular BMR matches typical in vivo values for the organism to be modeled. (b) Failure to account for the context-dependent behavior of cells can substantially alter the modeled system BMR, especially for larger animals 25, 28 . Graphs reproduced using previously published data and relationships 25, 28, 72 .
blood substitute for use in an HOC 22, 23, 37 , we propose limiting oxygen availability to manipulate cellular BMR 24 . Combined with other O 2 sensing and control systems 32−34 , we may achieve normoxic or (where necessary) hypoxic conditions in situ to ensure that both cell-and systemlevel metabolic rates are appropriately scaled to those of a full-size human.
AN EXAMPLE OF EXTRA-PHYSIOLOGIC SURVIVAL:
THE ICEFISH Th e design modifi cations proposed in the previous section beg the question of whether such extreme departures from expected physiologic parameter values are acceptable. Would an organism with drastically altered blood O 2 carrying capacity or completely lacking hemoglobin be viable at all? Fortunately, Nature herself has provided a unique example of such extra-physiologic adaptation and survival. The family Channichthyidae (sometimes called 'icefi sh') comprises hemoglobin-negative (Hb-) fi sh living in the Antarctic waters of the Southern Ocean. First documented in the 1840s, initial attempts to examine the fish were thwarted by an uncooperative cat who absconded with the specimen before it could be further studied 38 . Subsequent investigations highlighted family members' , including Chaenocephalus aceratus' (Fig. 3a) , startling lack of blood pigment and hemoglobin (Fig. 3b ) [39] [40] [41] [42] . Just as technical and fundamental limitations force HOC designers to contort system parameters in strange or unexpected ways, so too has nature forced C. aceratus to counter its own maladaptation in order to survive.
To demonstrate, and perhaps learn from, this extraphysiologic survival, we examine the fi sh in more detail. As a control, we use a cousin of C. aceratus, Notothenia coriiceps (also called neglecta), from the common suborder Notothenioidei 43 . N. coriiceps shares a similar environment and metabolic rate (measured by oxygen consumption) as C. aceratus 44−46 , but unlike the icefish, produces Hb at normal levels. Starting from a healthy N. coriiceps, we remove Hb and then apply the adaptations that allow C. aceratus to thrive: increasing cardiac output by a factor of nearly two and allowing for increased cutaneous respiration 40,41,44−48 . Th e result is a test-fi sh with several surprising extra-physiologic features, but nevertheless capable of survival (Supplementary Table  1 ). In particular, the ability of C. aceratus to absorb oxygen through its skin evokes polydimethylsiloxane (PDMS) -a common polymer in microfluidic and biomedical research applications that has similar properties of gas permeability (Supplementary Information S1.2). In addition to larger-thanexpected cardiac output, C. aceratus also has a blood volume of ∼90 mL/ kg, nearly twofold greater than the ∼50 mL/kg expected for a fish its size 42,46,49−51 . Another member of Channichthyidae, C. hamatus, has a blood volume over twofold its predicted value 49 . These Hb-fish substantially exceed expected blood volumes yet thrive (Supplementary Information S1.3), reinforcing the idea that extra-normal physiology can be an acceptable mechanism to survive in the face of limitations. Related to that increased blood volume, C. aceratus also exhibits increased capillary density. Recent results demonstrated that three diff erent metrics of vascularization were all ∼twofold greater in C. aceratus than in N. coriiceps (Figs. 4a and 4b ) 52 . Th erefore, even though blood fl ow rates are double in C. aceratus, so too is organ blood volume, indicating that tissue residence times -a key parameter in PB-PKPD models -should also remain unchanged between it and N. coriiceps.
Th is increased vascularity also helps compensate for dilution of soluble factors (e.g. O 2 , drugs or hormones) due to increased blood volume. At steady state the perfusion-limited diff usion of molecules from blood into tissue is described by Equation (1):
where C is the concentration, D is the diff usion coeffi cient and R is the uptake of solute by cells, governed in this case by Michaelis-Menten kinetics 17, 53 . Although a decrease in blood concentration leads to a decrease in potential gradient to drive diff usion, a corresponding decrease in intervessel distance (IVD) suggests that solute penetration may be similar, shown here specifi cally for O 2 ( Fig. 4c ; parameter values in Supplementary Information S1.4). Th is icefi sh adaptation is another example of nature fi nding a holistic, multi-faceted solution to physiologically challenging conditions. Of course, applying designs such as these to an HOC may still introduce problems with drugs or molecules that act in a concentration-dependent manner on the blood vessels themselves as well as other unforeseen consequences. Conversely, these data also suggest that depletion of soluble factors (e.g. oxygen) could be achieved over shorter distances, an important design consideration for engineering organ compartments such as the liver 17, 54 . Nevertheless, this preliminary analysis demonstrates that blood O 2 carrying capacity and the presence of Hb may be tuned to counter maladaptations -or possibly induce more appropriate cellular metabolic behavior. Th e icefi sh further suggests that increased blood volumes may be accommodated without drastically altering organism pharmacokinetics or certain stromal solute concentration gradients.
A DISTRIBUTION-INFORMED APPROACH TO
HOC BLOOD VOLUME Designing an HOC according to QPSRs alone would result in a system blood volume of ∼6 μL, too small for even cutting-edge microfl uidics and an acknowledged problem in the fi eld 7, 18, 21, 22, 24 . Although a 10× (or greater) increase would yield an HOC with a more manageable circulating volume, it would also dilute soluble factors and strain physiology to a much greater extent than the ∼twofold increase in volume observed in C. aceratus. Th erefore, we adopt a pharmacokinetic approach to investigate whether and to what extent the blood volume of an HOC can be increased while maintaining physiological relevance.
When a drug is administered, only a portion circulates dissolved in the blood. Accordingly, pharmacologists defi ne volume of distribution, V D , to describe how much drug is available in the plasma compared to the initial dose 55, 56 . Conceptually, V D closely resembles a partition coeffi cient describing the equilibrium distribution of a drug between the body and the blood. Using a slightly diff erent approach, we consider the distribution of a drug between body water -including blood -and tissue. Th erefore, this treatment is most applicable to small, perfusion-limited drugs without substantial serum protein binding. Th is ratio, K, is defi ned by Equation (2):
where K is the partition or distribution coeffi cient, C T is the concentration of drug in body tissue and C W is the concentration of drug in body water. Ignoring excretion and metabolism and devolving the concentration terms to amount over volume,
where Dose is the total amount of drug in the system, X W is the amount of drug in the body water, V T is the tissue volume and V W is the volume of body water. Assuming no diff erence in concentration of drug in body water and concentration of drug in blood (C B ) and introducing V O for non-blood body water volume (i.e. V W = V B + V O ), we rearrange to obtain Equation (5): If we apply an arbitrary Z-fold increase to the blood volume compartment and normalize the result to the Z = 1 condition, C B0 , Equation (6) follows:
In general, C B falls as 1/Z. However, the partitioning properties of the drug and the fact that V B is a small fraction of the total system water volume serve to substantially temper the eff ect of increasing Z on blood concentration (Supplementary  Information S2) . For example, this treatment suggests that a highly hydrophilic drug, epinephrine, can tolerate ∼10× increase in blood volume with only a ∼twofold change in blood concentration. More hydrophobic drugs, such as amiodarone, are predicted to show almost no change in blood level at higher values of Z, and would require ∼10 6 increase in blood volume to approach that same two-fold dilution.
To test these predictions, we construct a simple model of the body mimicking the two-compartment structure of our theoretical treatment. Th e water compartment, including variable blood volume, is represented by phosphate buff ered saline and tissue is represented by an organic liquid (here, 1-octanol). The concentration of three small-molecule drugs -epinephrine, propranolol and amiodarone -was measured and normalized to the Z = 1 condition. Th e data (mean ± S.D.), along with curves representing the values predicted by Equation (6) are plotted in Fig. 5a . All three cases show reasonable agreement between predicted and experimental values. For scenarios where even these small dilutions are unacceptable, or in instances where the preceding treatment does not apply, other pharmacokinetic-based approaches may be useful, especially if PDMS or another gas-permeable material is used to decouple O 2 delivery from blood fl ow rate (Supplementary Information S3).
To illustrate this concept another way, we hold the aqueous phase constant, vary the mass presence of an organic depot (here represented by adipose spheroids instead of octanol) and assay for health of a HepG2 liver cell monolayer in the presence of diff ering concentrations of hydrophobic (amiodarone; V D = 4,260 L for a 70-kg man) and hydrophilic (acetaminophen; V D = 66.5 L) drugs. According to Equation (6), the high value of P for a hydrophobic compound amplifi es the eff ects of increasing organic phase mass, leading to substantial protection of the HepG2 monolayer even at >10× the lethal concentration of amiodarone; the same changes in the face of increasing acetaminophen dosing shows no such eff ect (Fig. 5b) . Combined with the theoretical treatment developed here for solutes of varying hydrophobicity in aqueous and organic phases of varying volume, these results demonstrate that HOC designers may be able to systematically predict the eff ects of changing system fl uid volumes and therefore compensate for such changes in their experimental design.
HOC DESIGN

Organ compartment design strategy
To design each organ compartment, we build on metabolically supported functional scaling (MSFS) strategies proposed previously, as well as other, similar, schemes 22, 24, 57 . Th e specifi c approach of Moraes et al. classifi es organs according to principle function: two-dimensional (F-2D) or membranous tissue (e.g. lung) is scaled by surface area while functionally three-dimensional (F-3D) or lobular tissue (e.g. adipose) is scaled by volume 24 . Since this approach relies on principles of Euclidian geometry, it avoids inconsistencies that appear when empirical laws are extrapolated outside the range of the original dataset -a key problem for applying empirical, allometric organ-organism size relationships to HOC design 22, 23 . Design parameters for F-2D organs are achieved by scaling according to surface area and compartment size is selected to match fl uidic shear values found in vivo for each tissue. F-3D organs are simply scaled by mass. For more complicated organs that may be classifi ed as both F-2D and F-3D (e.g. liver), we used a two-compartment approach: one section with high surface area and another with high mass that together approach the appropriate values ( Table 2 ). Spheroids and other tissue aggregation strategies may be particularly useful in these cases (Supplementary Information S4) . The endothelium presents another special case. Since several sources estimate the endothelial surface area of the body at 1,000 m 2 or greater 58−60 , including the whole of the endothelium in this HOC would be an impossible undertaking. Since the endothelium mainly acts in concert with its associated organ rather than as a distinct entity, we include only endothelial tissue from organs already represented in this model (lung and liver). Th ese tissues serve to recapitulate endothelial cell function within the organs included in this design and also provide a readout for general endothelial "health" across the HOC.
In addition to the organs explicitly included in this HOC design, we must also account for the body volume not represented by any of the designated organ compartments. Including a blank "other organs" zone to represent implied (but absent) organs ensures that our total system mass will be commensurate with that of a macro version and other groups have included "missing organ formulators" and "other tissues" compartments to similar ends 19, 20, 22, 24 . Importantly, since we justify a substantially increased blood volume based in part on a volume distribution-based treatment that considers the entire body volume, it is critical that volume be faithfully replicated in our model system.
Overall design
parameters Th e insights provided by our examinations of metabolic scaling, C. aceratus' unique physiology, and volume of distribution considerations indicate that we need not be confined by preconceived notions of what is or is not "physiologic" in designing an HOC. Instead, it is the ultimate response -the function -of the HOC and not the underlying structure that is paramount. It is necessary to note here that increasing blood volume is not at odds with our proposal to limit oxygen supply. Since Henry's law dictates that the concentration of gas dissolved in a liquid is proportional to the partial pressure of that gas in the atmosphere and (as Fig. 2 demonstrates) cell consume oxygen in a concentration dependent manner, the overall blood volume should have little bearing on the matter in an oxygen controlled environment. If, rather than controlling the pO 2 of the culture atmosphere, a researcher sought to generate low O 2 by balancing gas exchange, consumption and fl ow 61 , then changing blood volume may indeed necessitate a careful balance of various parameters (e.g. fl ow, volume, cellular O 2 consumption and media oxygen concentration).
Finally, we formalize a complete set of design parameters for a lung, liver, endothelium, fat, and heart ×10 -6 HOC ( Table 3 , other tables and comparisons in Supplementary Information S5) that follows the design principles laid out here. We further compare relevant design criteria of this more practical ×10 -6 HOC to C. aceratus, a standard human, and a mouse (Fig. 6a) . Values for this fi ve-parameter comparison across blood oxygen content (blood O 2 ), intervessel distance (IVD), skin gas exchange, cardiac output and blood volume were drawn from many sources and normalized against values predicted by QPSRs 17, 23, 40, 46, 48, 49, 51, 52, [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] . For details, see Supplementary Information S6. Another set of charts predicting behavior based on these parameters is calculated and shown (Fig. 6b) , demonstrating the superiority of our holistic design strategy over an unmodifi ed approach. Inspired by the example of C. aceratus and motivated to suppress cellular BMR to physiologic levels (and to avoid the challenges inherent in developing a synthetic substitute), we have deliberately excluded Hb from this HOC design in order to restrict oxygen availability and limit cellular BMR. However, Hb also plays a key role in transporting carbon dioxide away from metabolically active tissues -carrying up to 30% of the CO 2 transported in blood 70 . In this HOC design, we justify ignoring these eff ects because CO 2 transport can occur by other means. At 35°C, PDMS is nearly fi ve times more permeable to carbon dioxide than oxygen 73 . Similarly, the solubility of CO 2 and NO (nitrous oxide, an important signaling molecule) in water are both orders of magnitude greater than O 2 74−76 . Beyond oxygen transport, Hb plays important roles in other aspects of physiology including NO catalysis 70 . Depending on the specifi c application, each function may need to be explicitly accounted for in HOC design.
For this (or any) HOC system to be accepted as a microphysiological model of the body, some method of validating the underlying design strategy is necessary. Although directly testing such a system against humans may be challenging, we can apply the same design criteria outlined here to build rats-, mice-, etc.-on-a-chip. Parallel studies comparing the response of the microphysiological model system to the genuine animal will provide information on areas where HOCs may be particularly well-(or ill-)suited to serve as a complimentary research tool. A second approach may be to test whether an HOC is able to maintain key homeostatic parameters (e.g. blood glucose level) in the face of a reasonable challenge (e.g. bolus injection of glucose). In and of themselves, these experiments may also yield new mechanistic insights into previously unexplored aspects of common biomedical research models.
CONCLUSION
Th is work makes several key assumptions that should be verifi ed, or at least noted, in further research. Although the section on 'Control of Cellular BMR' makes clear that we may indeed induce a more in-vivolike BMR in cells by controlling the concentration of oxygen available in culture, this is not the only criterion necessary for success. Many other factors including ECM support and cell-cell interaction, and likely some yet to be discovered factors, also drive in-vivo-like phenotypes and must be carefully considered as part of any HOC eff ort. Furthermore, for the treatment of the proposed distribution-informed approach to HOC blood volume to be valid, experimentalists must know, or at least be able to suspect, the chemical properties of all drugs, metabolites and other molecules of interest within a system. To be exhaustive within a generalized experimental model, it may be necessary for researchers to use iterative processes, where a system is screened for compounds of interest then tuned accordingly and rescreened. Finally, the F-2D and F-3D classifi cation proposed for HOC designs is likely too simplistic. While some organs fall readily into one category or the other, the truth is that most all organs behave somewhat like the liver -each has critical dependencies on both surface area and volume. To most accurately represent this reality, engineered, organ-specifi c on-chip systems would ideally represent organ compartment. However, in many cases constraints on resources and/or complexity will mean that F-2D and F-3D idealizations are suffi cient in most instances. Quarter power scaling relationships are both empirically and theoretically supported and provide guidance for sizing physiologic parameters in the face of changing system size. Th eir application to the development of microphysiological models of the body or "HOCs" however introduces both fundamental and technical challenges which currently frustrate eff orts at design and construction of a relevant, feasible system. We posit that HOC designers may avoid these issues by selecting parameters outside the realm of what is considered physiologic so long as the ultimate function of the system is preserved. Since cell behavior is context dependent, suppressing cellular BMR on-chip to mimic in-vivo levels is crucial to designing a physiologically relevant HOC. We observe O 2 -dependent decreases in cell metabolism across four diff erent cell types to demonstrate the feasibility of this approach. We use a natural experiment, the icefi sh, to conceptually justify this approach and demonstrate how extra-physiologic parameters may interact to give a normal physiologic response. Further study of an HOC system through a distribution-informed treatment of blood concentration of small-molecule drugs indicates that we may indeed increase HOC blood volumes with only minor consequences. In cases where even that is unacceptable, we provide frameworks to estimate the magnitude of and/or mitigate the error. Integrating these lessons in the design of a liver-lung-heart-fat-blood system, we propose a complete set of design parameters for a ×10 −6 miniaturized HOC system. Th is work forms a basis of a nature-inspired approach to govern the design of in-vitro model systems.
METHODS
Oxygen conformance and cellular BMR suppression
All cell lines were obtained from ATCC and cultured in Dulbecco's Modifi ed Eagle Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS) and 1% antibiotic/antimycotic (anti/anti). Th e day before the experiment, cells were seeded in 96-well plates at 25,000 cells/ well and allowed to adhere overnight. OxyCycler atmosphere control chambers (BioSphyrix, New York) were set to 2% and 7% oxygen, both with 5% CO 2 . Th e day of the experiment, media was changed to DMEM and anti/anti without FBS and one plate was placed in each oxycycler chamber, as well as a third plate in a standard cell culture incubator (20% O 2 and 5% CO 2 ) and allowed to equilibrate for four hours. At that point, the media was changed again and replaced with DMEM, anti/anti and AlamarBlue metabolic indicator (Invitrogen) . Aft er a two-hour incubation, the level of reduced AlamarBlue was measured using a fl uorescent plate reader (BioTek Synergy Neo) at 560/590 nm (excitation/emission). AlamarBlue indicates cell metabolic activity by serving as an oxidizing agent during aerobic respiration, competing with oxygen for electrons at the end of the electron transport chain 70, 77 . Changing oxygen levels, therefore, aff ect the frequency at which AlamarBlue is reduced and therefore the levels of fl uorescence observed across each cell culture plate at the end of the experiment. To correct for this eff ect, we use Equation (7) to estimate cellular metabolic activity in the face of changing oxygen level:
where Cellular BMR is the corrected, unitless cellular metabolic rate measured by AlamarBlue, AB Red is the fl uorescent measurement from the assay, ΔP AB is the diff erence in reduction potential between AlamarBlue and cytochrome C, the ultimate reducing agent of oxygen in aerobic respiration, X is the fractional reduction of oxygen tension compared to a 20% O 2 atmosphere (typical for a laboratory cell culture incubator) and ΔP O2 is the diff erence in reduction potential between O 2 and cytochrome C. Using standard values to calculate ΔP 77 , we can generate a corrected cellular BMR. We may use this unitless metric to compare relative cellular BMRs and to demonstrate the eff ect of oxygen tension on cellular metabolic activity. Two caveats must apply to this analysis, however. First, the cellular BMR values compared here are aerobic only; we make no eff ort to measure energy derived from fermentation. As respiration is an order of magnitude more effi cient, any error introduced by this approach is likely to be suffi ciently small. Second, while these cellular BMRs are purely relative measurements, one may theoretically use a series of calibration experiments to arrive at a set of absolute measurements for cellular metabolic rates.
Distribution-informed approach to HOC blood volumes
To test the theoretical predictions of Equation (6) regarding the behavior of small-molecule drugs in the face of changing blood volumes, we constructed a crude, ×10 −5 "pharmacokinetics-in-a-tube" system. A glass vial containing 280 μL of 1-octanol (Sigma) was used to model the tissue volume of a ×10 −5 human and 360 μL of pH 7.4 phosphate-buff ered saline (PBS, Life Technologies) represented the non-blood body water volume 55, 56 . A variable amount of PBS was used to represent Z = 1, 2, 5, 10, 30, 50 and 100 conditions, where Z = 1 corresponded to a blood volume of 60 μL. Th e relevant drug was added to the vial, agitated, and allowed to equilibrate for ∼two hours in a 5% CO 2 incubator at 37°C. Aft er ∼two hours, the organic and aqueous phases were well separated and the appropriate phase was sampled and analyzed. Each condition was performed in triplicate. For epinephrine (Sigma), a total dose of 100 μg/vial was used and the lower (aqueous) phase was sampled. Epinephrine levels were detected by an Acquity UPLC system (Waters) with a reverse-phase C18 column (Waters) and a UV-vis detector measuring absorbance at 210 nm. Th e mobile phase was 99% 20 mM NaH 2 PO 4 at pH 2.5 and 1% MeOH. For propranolol, a total dose of 1 mg/vial was used and the aqueous phase was sampled. Propranolol (Sigma) levels were detected on a Synergy plate reader (BioTek) by reading fl uorescence at 289/353 nm. For amiodarone (Sigma), the total dose/vial was 0.56 mg and the upper (organic) phase was sampled. Amiodarone levels were detected by fl uorescence at 388/475 nm.
To investigate the implications of changing organic phase mass on a living system, we used a liver-adipospheroid co-culture platform. 3T3-L1 preadipocytes were expanded and diff erentiated into adipose tissues in 3D spheroid culture as described previously with 8,000 cells per spheroid 24 . HepG2-C3A liver cells were seeded in a clear bottom, black-wall 96-well plate (Corning Costar) at a density of 10,000 cells/ well and given six hours to attach. Aft er adipose spheroid diff erentiation, the spheroids were collected from the hanging drop plate and added to the 2D liver cell culture (0, 4 or 12 per well) in 30 μL of media volume. Amiodarone (dissolved in DMSO) and acetaminophen were then added to the culture wells and incubated for 24 hours. Aft er the incubation period, media and spheroids were aspirated and the HepG2-C3A monolayer was washed once gently and AlamarBlue indicator was added. HepG2 viability was measured by taking a fl uorescence reading at 560/590 (ex/em) aft er two hours. Data was analyzed using two-way ANOVA with Tukey's post-test.
SUPPLEMENTARY INFORMATION
S1. Icefi sh analyses S1.1 Detailed derivation of extra-physiologic parameter comparison between Notothenia coriiceps and Chaenocephalus aceratus
Here, we use a natural experiment to demonstrate that the absence of hemoglobin (Hb) alone does not doom a vertebrate -or our HOCex ante. Furthermore, this extra-ordinary example -nature using two wrongs to make a right -illustrates workarounds and adaptations that may be generally useful to HOC designers. S1.1.1 Antarctic, hemoglobin-positive (Hb+) fi sh deliver suffi cient O 2 through blood A thorough examination of the oxygen delivery system of an Hb-less (Hb−) animal can provide both specifi c and abstract clues for addressing fundamental and technical challenges of HOC design. We begin by examining C. aceratus' cousin, Notothenia coriiceps (also called neglecta), from the common suborder Notothenioidei S1
. N. coriiceps is also found in the ice-cold waters surrounding Antarctica but unlike C. aceratus, the fi sh expresses Hb at normal levels. Further, literature reports indicate that N. coriiceps and C. aceratus have overlapping ranges of metabolic rate, as measured by oxygen consumption S2−S4 . By methodically imposing some of the characteristics that make members of the family Channicthyidae special upon a hypothetical N. coriiceps test-fi sh from a similar environment we can learn how those adaptations may inform our own design and fabrication of a human on a chip system whose parameters will inevitably deviate from actual humans to some degree.
To examine how much oxygen is delivered by the blood for a given scenario, we multiply the cardiac output, Q (normalized for a 1 kg fi sh, the approximate average mass for both C. aceratus and N. coriiceps) S2-S5 , by the oxygen blood level, BL O2 . Since reptiles, amphibians, fi sh and even (in limited cases) mammals have been known to conduct gas exchange through the surface of their skin S6 , we also use published reports to account for this source of oxygen. Comparing the results to measured oxygen consumption values, VO 2 , we may assess whether the circulatory system of the fi sh is can support its metabolism. Previous studies on N. coriiceps measured a resting Q of 3,900 mL blood/hour S5 . Since this fi sh produces Hb, BL O2 is 0.06 mL O2/mL blood S7 . Th erefore, the circulatory system of the fi sh can deliver 230 mL O 2 /hour or, at 0°C and atmospheric pressure, 330 mg O 2 /hour. Since the cutaneous respiration of larger, scaled fi sh is generally small S8 , we omit any "skin breathing" adjustment for N. coriiceps. At rest, the average VO 2 Beyond increased cardiac output, members of Channicthyidae have also been shown to be capable of a signifi cant amount of gas exchange across their skin. One study estimated that cutaneous respiration could account for approximately 40% of C. aceratus' oxygen uptake, partially due to its lack of scales S4,S10 . Surprisingly, C. aceratus' mass is nearly an order of magnitude larger than most other animals that exhibit similar percentage levels of cutaneous respiration S8,S11 . Since C. aceratus' large size implies a lower surface-area-to-volume ratio, we would expect lower percentage levels of dermal gas exchange. Instead, these high levels indicate that skin breathing is another way the fi sh copes with a lack of Hb. Including this new level of cutaneous respiration in the list of adaptations for our test-fi sh, we fi nd that it can deliver 78 mg O 2 /hour which is still small, but at least approaches the same order of magnitude for N. coriiceps (main text, Table 1 ).
This level of cutaneous respiration corresponds to an oxygen permeability of ∼1 × 10 −11 mol/m/s/mmHg for Channichthyidae skin (calculated from several sources, details in Supplementary Information S1.2) S3,S4,S12 , the same order of magnitude as the 3.8 × 10 −11 mol/m/s/mmHg reported for polydimethylsiloxane (PDMS) S13 , an elastomer common to microfluidics. Intriguingly, the use of gaspermeable PDMS devices to ensure proper oxygen delivery to tissues in a microfabricated HOC may have precedent in nature.
C. aceratus's ability to compensate for the low O 2 carrying capacity of its blood indicate that our own eff orts to tune the O 2 carrying capacity of an HOC blood surrogate, or lack of a Hb analog therein, do not doom such eff orts ex ante. Th is short exercise shows that Nature herself occasionally employs "engineering workarounds" and that extra-normal physiological values may be compensated by adjusting other parameters. In this case, two (carefully considered) wrongs can make a right. Further, C. aceratus demonstrates the value of introducing decoupling or redundant mechanisms to control important physiological parameters (e.g. vascular and cutaneous gas exchange to control O 2 delivery). Th ese changes are not only useful for overcoming maladaptation, but also give designers a broader parameter space that can be used to achieve physiological relevance.
S1.2 Calculation of C. aceratus skin permeability
Th e following steps were used to calculate the permeability of C. aceratus' skin to molecular oxygen. Th e equation 
S1.3 Further details on icefi sh blood volume S1.3.1 Comparison of blood volume as a function of body size
In addition to larger-than-expected cardiac output (mediated by a larger heart mass-body mass ratio) S16 , C. aceratus also has a blood volume of ∼90 mL/kg, nearly twofold greater than the ∼50 mL/kg predicted for a fi sh its size S4,S17-S20
. Another member of Channichthyidae, C. hamatus, has a blood volume over two-fold its predicted value S17 . Th ese Hb− fi sh significantly exceed the blood volume expected from conventional quarter-powered scaling relationships (QPSRs) yet manage to function and fl ourish (Supplementary Table 1) . Importantly, this observation reinforces the idea that extra-normal parameters can be an acceptable mechanism to thrive in the face of surprising physiology.
S1.3.2 Energy cost associated with increased blood volume
Th e increased blood volume shown in certain Hb− Channichthyidae species means that C. aceratus' heart must exert more energy to circulate that volume, especially at the high cardiac output required to maintain tissue oxygen levels. Researchers have estimated that C. aceratus allocates over one-fi ft h of its energy to driving circulation and that such a cost tradeoff off sets any gains in energy conservation made as a result of lower blood viscosity due to the loss of hemoglobin S9,S10 . While this increased energy demand for circulation (driven mostly by a larger stroke volume rather than a faster heart beat) is certainly a concern for C. aceratus S3,S9,S24 , it could easily be addressed in an in-vitro system with the use of external assist devices, such as pumps S25−S27 , to make up for the energy defi cit imparted by elevated blood volumes.
S1.3.3 Increased vascular density and vessel bore diameter
Observations of increased vascular density in C. aceratus S28 , made in retinal tissue, stand in contrast to other studies of icefi sh muscle that found decreased capillary density S24,S29 . Th ese muscle studies, however, also noted larger muscle fi ber size in Hb− Channichthyidae compared to their Hb+ cousins. One group observed that such an increase in size would also decrease the rate of current leak from the muscle, conserving a substantial amount of energy and thereby decreasing the metabolic demand of the tissue S29 . Th erefore, measurements made in the retina, where no special adaptations (other than increased capillary density, of course) have been observed and oxygen demand is largely activitylevel agnostic, may be a more faithful representation of the overall character of the fi sh. Furthermore, the large vessel diameters observed in C. aceratus may be explained by constitutive overexpression of NO, a potent vasodilator S19,S28 . Since Hb-derivatives are involved in the major pathway for NO elimination S30 , their absence explains this overexpression and dictates that capillary diameter may not deviate as sharply from values predicted by scaling theory as initial reports indicate S22,S23,S28,S31 . In an HOC, NO elimination in the absence of Hb may be achieved by incorporating PDMS, which is highly permeable to gases S13 , as well as taking advantage of the greater solubility of NO in liquid S32 .
S1.4 Comparison of oxygen tissue penetration
between Hb+ and Hb− Antarctic fi sh To model how the tissue penetration of oxygen may vary between C. aceratus and its Hb− cousin, N. coriiceps, we start with Equation (1) from the main text, describing the perfusion-limited diff usion of molecules from blood into tissue:
where D = diff usion coeffi cient, C = concentration of oxygen and R = uptake of oxygen by tissue, governed by Michaelis-Menten kinetics.
In the special case of one-dimensional diffusion, the equation simplifi es to:
where Ω = O 2 consumption per cell, γ = cell density in vivo and K M = Michaelis constant.
Th e above equation was solved numerically using MatLab and the parameters described in Supplementary Table 2 for the case of a Hb− Antarctic fi sh (C. aceratus) and an Hb+ Antarctic fi sh (N. coriiceps). By setting suffi ciently positive and negative x-values equal to the boundary condition, C C , we achieve the two boundary conditions necessary to solve the equation. Th e resulting solution is cut in half about the y-axis and a lower threshold of 2 × 10 -2 mol O 2 ⋅ m -3 is imposed to represent the limit of cellular function S33 .
S2. Full derivation of distribution-informed approach to HOC
blood volume Starting from Equation (2) of the main text, we derive the relationship expressed in Equation (6) relationship can be expressed as a ratio of concentrations, also called a partition coeffi cient, K.
where K = partition coeffi cient, C T = concentration of drug in body tissue and C W = concentration of drug in body water.
Ignoring excretion and metabolism and devolving the concentration terms to amount over volume we obtain
where Dose = total amount of drug administered, X W = total amount of drug in body water, V T = volume of body tissue, and V W = volume of body water.
Assuming no difference in concentration between blood and extracellular water, we rearrange to eventually arrive at Equation (5) of the main text
where V B = blood volume, V O = non-blood body water volume and C B = concentration of drug in the blood = C W = concentration of drug in body water.
Allowing blood volume to vary by an arbitrary multiple, Z, we obtain
where Z = arbitrary blood volume multiplier.
Normalizing the result to a standard condition of Z = 1, we derive an expression for the normalized blood concentration of a small molecule drug of distribution coeffi cient, D, in the face changing blood volumes, Equation (6) of the main text:
where C B0 = concentration of the drug in blood for Z = 1.
S3.
Other pharmacokinetic approaches to compensate for high HOC blood volumes for perfusion/transport limited substances Classical pharmacokinetic/pharmacodynamics (PKPD) models address inter-organ interactions by using rate constants to account for mass transfer between diff erent compartments that may eff ectively capture clinical behavior but have little physiological signifi cance. Physiologically-based (PB-PKPD) models explicitly defi ne blood fl ow as the medium by which analytes move between compartments S35 . Although PBPK/PD models (also referred to as 'fl ow models') require extensive information about fl ow rates, compartment volumes and reaction rates, they also require less data fi tting, are better able to accommodate pathological conditions, and are more easily extrapolated to describe PKPD behavior across species S36 . In Section 3 of the main text, we explored one way in which specifi c drug properties could be used to improve the effi cacy of our HOC with super-physiologic blood volume (or estimate the error introduced by such an approach). Here, we further examine PB-PKPD approaches to mitigate any residual mismatch between HOC drug concentration levels and those that may occur in the body. We sketch out approaches to maintain steady state tissue concentration in the face of fi rst order (Supplementary Information S3.1) and Michaelis-Menten reaction kinetics (Supplementary Information S3.2) , as well as techniques to hold half-life (Supplementary Information S3.3) and area under the curve (Supplementary Information S3.4) constant from human to HOC. It should be noted that each of these approaches comes with its own set of caveats. For example, area under the curve (AUC) can be a useful metric for assessing total exposure, but can also mislead when diff erent exposure profi les have the same AUC value but fall below or exceed certain critical thresholds such as minimum eff ective concentration or minimum toxic concentration. . Assuming fi rst-order reaction kinetics where the rate of reaction depends linearly on the concentration of the solute of interest within the compartment, as has been described previously S39 , we begin with the mass (or molar) balance for a particular solute in the tissue compartment:
S3.1 PB-PKPD
which describes the mass balance of a CSTR-idealized organ compartment where: Assuming steady state (dX T /dt0) and replacing X T /V T with C T-SS , the steady-state concentration in the tissue compartment, we obtain:
Solving for C T-SS yields the following:
We now reduce the blood concentration, C O , by a blood volume increase induced dilution factor, J (which can be estimated from the distribution-based treatment outlined in Section 3 in the main text and Supplementary Information S2, for example, in the face of a 10× blood volume increase, J = 2.28 for epinephrine, J = 1.06 for propranolol and J = 1 for amiodarone), and introduce a new tissue fl ow rate, P T :
where J = dilution factor induced by blood volume increase, depending on both drug properties (D) and magnitude of blood volume increase (Z).
Since we wish to maintain C T-SS across both scenarios, we set the two preceding equations equal and solve for P T , yielding:
Th erefore, if fractional fl ow rates to each organ and other relevant parameters are maintained, a new system fl ow rate (cardiac output) can be selected to maintain steady-state tissue level of a specifi c drug. Th is approach may be especially useful if another method (e.g. incorporation of gas permeable materials such as PDMS) is used to decouple oxygen delivery from blood fl ow.
S3.2 PB-PKPD treatment to maintain steady-state tissue
concentration with Michaelis-Menten kinetics A more complicated, but perhaps more realistic, treatment involves assuming Michaelis-Menten reaction kinetics in the organ compartment. We note that Michaelis-Menten kinetics have previously been used to numerically model oxygen consumption within a bioreactor S33 as well as toxicity of an anti-cancer drug in a three-organ HOC S38 . Starting with the mass balance:
Expanding and collecting terms gives:
( )
Using the quadratic formula to solve for C T-SS yields:
At this point the analytical treatment becomes quite cumbersome. Th e interested reader may obtain a solution for an adjusted fl ow rate, P T , as in Supplementary Information S3.1, or may instead choose to solve the problem numerically as done previously S33,S38 .
S3.3 PB-PKPD treatment to maintain half-life
Drug half-life is another important parameter that concerns pharmacologists S40 . Half-life, HL, can be described by the following equation:
where Q = fl ow rate, V = compartment volume and K P = equilibrium partition coeffi cient.
Th erefore, half-life is unaff ected by changes in blood volume.
S3.4 PBPK/PD treatment to maintain AUC
AUC is a common metric for assessing patient dose S41−S43 . For example, if the clearance of a drug and its metabolites can be assumed to be perfusion limited -that is the rate of clearance from the bloodstream is much greater than the rate of delivery to clearing organ -decreasing the cardiac output will increase the AUC (or vice versa)
where X = the amount of drug administered in mg or moles, F Cl = clearance fraction of drug and Q = cardiac output.
Thus, even in the face of increased dosing as proposed above, engineering modifi cations can be used to maintain other important pharmacokinetic parameters such as AUC. Using the open-source PKQuest PBPK modeling soft ware we can examine how dose and cardiac output may be manipulated to preserve AUC (Supplementary Fig. 1 ) S45-S47 . Critically, uncoupling these and other parameters -as we have begun to attempt here -will off er technologists multiple axes along which to tune exposure profi les and represents one potential solution to overcoming the substantial engineering challenges of developing a micro-scale model of the human body.
S4. Surface area-mass considerations for 3D constructs in an
HOC system Three-dimensional (3D) tissue constructs can lead to improved phenotype and function in-vitro for a variety of cell types, including liver cells S48 . Using 3D aggregates also introduces a more complicated relationship between mass and surface area. For this reason, spheroid size and number must be carefully considered during design. Below is a graph representing the relationship between HOC organ mass and surface area for spheroids of various sizes (Supplementary Fig. 2 ). Since spheroids of diameter 250 μm have been shown to exhibit highest levels of liver specifi c function (unpublished data), the dashed, purple curve is used to inform our design process.
S5. Other HOC design-related tables S5.1 Comparison between ×10
−6 HOC and a macro-and micro-human We can compare the organ-and system-level parameters for our ×10 
Supplementary Figure 2
Cell-dense 3D tissue constructs (spheroids) can control the relationship between tissue surface area and volume. Depending on spheroid diameter, different surface area-volume curves may be obtained. values predicted by QPSR for a mini-human. Like Fig. 7 of the main text, these comparisons highlight ways in which our HOC design departs from known or predicted values.
Supplementary
S5.2 Design parameters for HOCs of other sizes
For convenience and completeness, design parameters for two other HOCs (×10 −4 and ×10 −7
) are presented here.
S6. Derivation of design radar charts S6.1 Creation of radar charts
To create radar graphs of Fig. 7 of the main text for human, mouse, icefi sh and ×10 -6 HOC, observed values were normalized against scaling values and plotted along fi ve log 10 axes in Microsoft Excel.
S6.2 C. aceratus radar chart normalized against
N. coriiceps Since C. aceratus is poikilothermic, metabolic values for the fi sh are likely substantially aff ected by ambient temperature. Although several correction factors have been proposed to compare cold-water fi sh to animals with warmer body temperatures S55,S56 , no reliable method exists to adjust all relevant parameters considered here. One way to circumvent this problem is to normalize C. aceratus to another fi sh from the same environment that can be assumed to follow conventional scaling laws that describe most of the rest of the natural world. For completeness, this chart for C. aceratus normalized against N. coriiceps is included here (Supplementary Fig. 3 ). α -Design consideration to induce in-vivo-like cellular BMR (see Section 2 of main text). β -Design consideration arrived at by applying QPSR isometric scaling of blood volume to miniaturize human by six orders of magnitude. Th e resulting value (6 μL) is adjusted upwards by a factor of 10 to achieve a more workable volume. γ -Design consideration arrived at by applying QPSR ¾-power scaling of cardiac output to a ×10 −6 miniaturized human. δ -Design consideration to accommodate liver spheroids of 250 μm in diameter. 
Supplementary
S7. Explanation of M1 scaling for F-2D and F-3D organs
An interesting consequence of this strategy is that, by virtue of holding cell BMR constant, it abolishes the M 3/4 dependence of system BMR, instead replacing it with an M 1 dependence and causing the relationship between human and HOC system BMR to lie on a fundamentally diff erent trajectory than human-animal (Supplementary Fig. 4) . Th is explains why both F-2D and F-3D organs are scaled as M 1 .
